Presentation to J.P. Morgan Healthcare Conference and Q4 2022 Illuccix Revenue Update
MELBOURNE, Australia, Jan. 9, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises it is presenting at the 41 st Annual J.P. Morgan Healthcare Conference (9 – 12 January) in San Francisco. As part of the Company's presentation (available to view o...
ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances
* Complete data from global Phase III ZIRCON study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) will be presented at American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium (ASCO GU) inFebruary 2023 * Telix pipeline...
Telix Announces Executive Leadership Appointments
MELBOURNE, Australia, Dec. 5, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession planning. Richard Valei...
Illuccix® Available on High Activity Gallium Generator Technology to Meet High Demand
INDIANAPOLIS, Nov. 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) with up to 50mCi for radiolabeling is available for use on 100mCi (millicurie) gallium generators, an ...
First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy
MELBOURNE, Australia, Nov. 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in patients with rec...
Telix Acquires Optimal Tracers
MELBOURNE, Australia and INDIANAPOLIS, Ind., Nov. 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement withSacramento-based Northern California PET Imaging Center (NCPIC) to acquire Optimal Tracers, a radiochem...
Telix to Present at Jefferies London Healthcare Conference 2022
MELBOURNE, Australia, Nov. 11, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company), a commercial-stage biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals, advises that DrChristian Behrenbruch,...
Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study
Summary of Study Outcomes * ZIRCON Phase III study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) has met all of its primary and secondary endpoints * The study delivered co-primary endpoints of 86% sensitivity and 87% specificity and 93% posit...
Telix Recognised as Company of the Year at AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards 2022
MELBOURNE, Australia, Oct. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is today pleased to announce that it has been awarded Australian Company of the Year in the 2022 AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards, held today at t...
Telix and UniQuest to Collaborate on Radiolabelled Immune Targeting Peptide
MELBOURNE, Australia, Oct. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a collaboration with UniQuest Pty Ltd (UniQuest), the commercialisation company of TheUniversity of Queensland (UQ), to develop a radiolabelled molecule targeting an im...
Telix Reports Third Quarter 2022 Financial Results
MELBOURNE, Australia, Oct. 20, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended30 September 2022 (Q3 2022). All figures are in AUD$ unless otherwise...
TLX250-CDx Indication Expansion: Preliminary Data Presented at EANM
* OPALESCENCE Phase II feasibility study of TLX250-CDx in patients with triple-negative breast cancer – early results suggest potential to detect carbonic anhydrase IX (CAIX) expression, theranostic potential in this difficult to treat disease. * PERTINENCE Early Phase I feasibility study of ...
Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market
* New agreement adds two Telix investigational PET imaging radiotracers to GE Healthcare's immuno-diagnostic portfolio, to enable patient selection and monitoring in immunotherapy trials * Telix tracers evaluate levels of carbonic anhydrase IX and lactate in tumours to inform and improve ther...
Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging
MELBOURNE, Australia, Oct. 17, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved an investigational new drug (IND) application to commence...
Health Canada Approves Illuccix® for Prostate Cancer Imaging
MELBOURNE, Australia, Oct. 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that Health Canada has approved Illuccix® [kit for the preparation of gallium (68Ga) gozetotide injection] for use in staging and re-staging intermediate and high-risk prost...
First Patient in New Zealand Dosed with Illuccix® - Telix's Prostate Cancer Imaging Agent
MELBOURNE, Australia, Sept. 30, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the first commercial dose inNew Zealand of its prostate cancer imaging agent, Illuccix® (Kit for Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known ...
Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate
MELBOURNE, Australia, Sept. 28, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved a pivotal Phase III registration study that will bridge ...
First Patient in Australia Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent
MELBOURNE, Australia, Sept. 28, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the first commercial dose inAustralia of its prostate cancer imaging agent, Illuccix® (Kit for Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known as...
First Patient Enrolled in ProstACT TARGET Study
MELBOURNE, Australia, Sept. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and GenesisCare, the largest provider of integrated cancer care inAustralia, today announce that a first patient has been enrolled in the Phase II ProstACT TARGET study of Telix's pro...
Final IPAX-1 Study Data Confirms Safety and Tolerability Profile for TLX101, Preliminary Efficacy Data
MELBOURNE, Australia, Sept. 21, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today reports the final results from the IPAX-1 Ph I/II study of TLX101 therapy (4-L-[131I] iodo-phenylalanine, or 131 I-IPA) in combination with external beam radiation therapy (EBRT)...
